INDV Indivior PLC Ordinary Shares

Indivior PLC's stock has experienced significant volatility due to ongoing legal and regulatory challenges, despite a positive long-term outlook in addiction treatment. Investors are weighing these risks against the company's strong fundamentals and resilient revenue growth. Wall Street analysts are cautiously constructive, indicating a balanced risk-reward profile, with further clarity on litigation needed for a more decisive upward re-rating.

Indivior PLC announced its inclusion in the S&P SmallCap 600 index on December 22, 2025, a move that aligns with the company's U.S. business focus. This inclusion places Indivior's shares within an index that tracks small-cap companies with market capitalizations ranging from $1.2 billion to $8.0 billion. The company aims to further grow its SUBLOCADE® treatment for opioid use disorder.

Indivior PLC (Nasdaq: INDV) has announced its inclusion in the S&P SmallCap 600® index, effective December 22, 2025. This inclusion signifies an important milestone for the company, aligning its capital markets presence with its U.S. business profile, especially concerning its SUBLOCADE® treatment for opioid use disorder. The S&P SmallCap 600 index measures the performance of small-cap companies in the U.S. equities market with market capitalization between $1.2 billion and $8.0 billion.

Indivior recently shared positive clinical data for SUBLOCADE and Phase II results for INDV-2000, leading to a significant increase in its share price. While the stock's 35.5x P/E ratio suggests it's overvalued compared to the industry average, a Discounted Cash Flow model indicates potential undervaluation. Investors are currently paying a premium, anticipating high future earnings growth for the pharmaceutical company.

Indivior's board has approved executive salary increases for its CEO and CFO, effective January 1, 2026, following a competitive market review. CEO Joseph Ciaffoni's salary will increase to $1,115,000, and CFO Ryan Preblick's to $604,000, aims to retain senior leadership. The company's stock, INDV, currently has a Hold rating from analysts with a $40.00 price target.

Indivior (INDV) recently released positive clinical trial results for SUBLOCADE®, demonstrating its efficacy in reducing opioid use and supporting abstinence, particularly among high-frequency fentanyl users. This enhanced effectiveness, especially with the 300-mg dose, strengthens the investment narrative for Indivior's core product. While the impact is medium-term, it supports future demand and pricing, alongside immediate catalysts like 2025 revenue guidance and a sole Nasdaq listing.